Identification

Name
Racepinephrine
Accession Number
DB11124
Type
Small Molecule
Groups
Approved
Description

Racepinephrine is a racemic mixture consisting of d-Epinephrine and l-Epinephrine enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Racepinephrine hydrochloride336096P2WE329-63-5ATADHKWKHYVBTJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
S2Solution2.25 %Respiratory (inhalation)Nephron Pharmaceuticals Corporation1998-10-02Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AsthmanefrinSolution11.25 mg/.5mLRespiratory (inhalation)Nephron Sc, Inc.2012-08-01Not applicableUs
Epi-MistAerosol, spray.594 mg/.12mLRespiratory (inhalation)Drnaturalhealing Inc2015-05-15Not applicableUs
S2Solution11.25 mg/.5mLRespiratory (inhalation)Cardinal Health2000-01-01Not applicableUs
S2Solution11.25 mg/.5mLRespiratory (inhalation)Nephron Sc, Inc.2000-01-01Not applicableUs
Categories
UNII
GR0L9S3J0F
CAS number
329-65-7
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Indicated for temporary relief of mild symptoms of intermittent asthma.

Pharmacodynamics

Epinephrine acts on α- and β-adrenergic receptors. When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action [Label]. Epinephrine induces bronchial smooth muscle relaxation to relieve respiratory distress in asthma. In a clinical trial of paediatric patients with bronchiolitis, administration of aerosolized racemic epinephrine via inhalation resulted in improved clinical symptoms such as wheezing and retractions [1]. The clinical efficacy of racemic epinephrine was comparable to that of salbutamol or albuterol, which are commonly used bronchodilators [1, 2].

Mechanism of action

Epinephrine is a non-selective agonist at α- and β-adrenergic receptors, which are all G-protein-coupled receptors. The main therapeutic effect of epinephrine arises from its agonist action on β2-adrenergic receptors, which activate adenylyl cyclase and increase intracellular cyclic AMP production. Epinephrine causes smooth muscle relaxation on various tissues, including bronchial smooth muscles [3]. As a result, epinephrine serves to alleviate bronchospasm, wheezing and tightness of chest that may occur during asthmatic attacks [Label]. Via its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder, epinephrine may also alleviate pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis.

Epinephrine also acts on the α-adrenergic receptors on vascular smooth muscles, particularly in the skin and splanchnic vascular beds, to cause constriction. Epinephrine is thought to reduce capillary leakage by constricting precapillary arterioles, reducing hydrostatic pressure and consequently bronchial mucosal edema [1].

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-1B adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AAlpha-2C adrenergic receptor
agonist
Human
ABeta-1 adrenergic receptor
agonist
Human
ABeta-2 adrenergic receptor
agonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
ABeta-3 adrenergic receptor
agonist
Human
Absorption

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Volume of distribution

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Protein binding

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Metabolism

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Route of elimination

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Half life

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Clearance

To refer to the pharmacokinetic data of L-epinephrine, refer to the drug entry for Epinephrine.

Toxicity

Oral LD50 of racepinephrine hydrochloride in mouse is 90 mg/kg [MSDS].

Overdosage of epinephrine may cause extremely elevated arterial pressure, which may further lead to cerebrovascular hemorrhage, particularly in elderly patients. Peripheral vascular constriction in conjunction with cardiac stimulation may produce pulmonary oedema. Treatment consists of rapidly acting vasodilators or alpha-adrenergic blocking drugs and/or respiratory support. Transient bradycardia followed by tachycardia may also be observed, and may be accompanied by potentially fatal cardiac arrhythmias. remature ventricular contractions may appear within one minute after injection and may be followed by multifocal ventricular tachycardia (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by atrial tachycardia and occasionally by atrioventricular block. In case of arrhythmias, treatment should involve administration of a beta­ adrenergic blocking drug such as propranolol. Overdosage may also produce extreme pallor and coldness of the skin, metabolic acidosis, and kidney failure, which should each be treated with suitable corrective measures [Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineRacepinephrine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Racepinephrine.Experimental
AcebutololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Racepinephrine.Approved, Vet Approved
AdrafinilRacepinephrine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineRacepinephrine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Racepinephrine.Approved, Withdrawn
AmibegronRacepinephrine may decrease the vasoconstricting activities of Amibegron.Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Racepinephrine.Illicit, Withdrawn
AmiodaroneRacepinephrine may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
AmitrazRacepinephrine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Racepinephrine.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Racepinephrine.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Racepinephrine.Approved
AmphetamineAmphetamine may increase the hypertensive activities of Racepinephrine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Racepinephrine is combined with Amrinone.Approved
AnisodamineRacepinephrine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineRacepinephrine may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineRacepinephrine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Aranidipine.Approved, Investigational
ArbutamineRacepinephrine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolRacepinephrine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
ArotinololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
AsenapineAsenapine may increase the antihypertensive activities of Racepinephrine.Approved
AtenololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Racepinephrine.Approved
AvanafilAvanafil may increase the hypotensive activities of Racepinephrine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Azimilide.Investigational
AzosemideRacepinephrine may increase the hypokalemic activities of Azosemide.Investigational
BambuterolRacepinephrine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Barnidipine.Approved
BefunololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Racepinephrine is combined with Bencyclane.Experimental
BendroflumethiazideRacepinephrine may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypertensive activities of Racepinephrine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.Approved, Illicit
BenzthiazideRacepinephrine may increase the hypokalemic activities of Benzthiazide.Approved
Benzylpenicilloyl PolylysineRacepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Racepinephrine is combined with Bepridil.Approved, Withdrawn
BetaxololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Racepinephrine.Approved
BioallethrinThe risk or severity of hypotension can be increased when Racepinephrine is combined with Bioallethrin.Approved, Experimental
BisoprololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BitolterolRacepinephrine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Racepinephrine.Approved
BrexpiprazoleBrexpiprazole may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
BrimonidineRacepinephrine may decrease the vasoconstricting activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Racepinephrine.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Racepinephrine.Investigational
BufuralolRacepinephrine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideRacepinephrine may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may increase the antihypertensive activities of Racepinephrine.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Racepinephrine.Approved
ButriptylineButriptyline may decrease the antihypertensive activities of Racepinephrine.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Racepinephrine is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypertensive activities of Racepinephrine.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Racepinephrine.Approved
CarvedilolThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
ChlorothiazideRacepinephrine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Racepinephrine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved
ChlorthalidoneRacepinephrine may increase the hypokalemic activities of Chlorthalidone.Approved
CilnidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Cinnarizine.Approved, Investigational
CirazolineRacepinephrine may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Racepinephrine.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Clevidipine.Approved, Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved
ClonidineRacepinephrine may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may decrease the bronchodilatory activities of Racepinephrine.Experimental
ClozapineClozapine may increase the antihypertensive activities of Racepinephrine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Racepinephrine is combined with Cyclandelate.Approved
CyclopenthiazideRacepinephrine may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DapiprazoleDapiprazole may increase the antihypertensive activities of Racepinephrine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Racepinephrine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Darodipine.Experimental
DesipramineDesipramine may decrease the antihypertensive activities of Racepinephrine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Racepinephrine.Approved, Investigational
DetomidineRacepinephrine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineRacepinephrine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the antihypertensive activities of Racepinephrine.Approved, Illicit
DibenzepinDibenzepin may decrease the antihypertensive activities of Racepinephrine.Experimental
DihydroergocornineDihydroergocornine may increase the hypertensive activities of Racepinephrine.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive activities of Racepinephrine.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive activities of Racepinephrine.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved, Investigational
DiltiazemThe risk or severity of hypotension can be increased when Racepinephrine is combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may decrease the antihypertensive activities of Racepinephrine.Approved, Withdrawn
DipivefrinRacepinephrine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Racepinephrine.Approved
DL-MethylephedrineRacepinephrine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Racepinephrine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Racepinephrine.Approved
DopexamineRacepinephrine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DosulepinDosulepin may decrease the antihypertensive activities of Racepinephrine.Approved
DotarizineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Dotarizine.Investigational
DoxazosinThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Doxazosin.Approved
DoxepinDoxepin may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Racepinephrine.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Racepinephrine.Approved, Illicit
DronedaroneDronedarone may increase the antihypertensive activities of Racepinephrine.Approved
DroperidolDroperidol may increase the antihypertensive activities of Racepinephrine.Approved, Vet Approved
DroxidopaRacepinephrine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Racepinephrine.Approved
EfonidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Efonidipine.Approved, Investigational
EpanololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Racepinephrine is combined with Eperisone.Approved, Investigational
EphedraRacepinephrine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Racepinephrine.Approved
EpinastineRacepinephrine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineEpinephrine may increase the antihypertensive activities of Racepinephrine.Approved, Vet Approved
EpitizideRacepinephrine may increase the hypokalemic activities of Epitizide.Experimental
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
EsatenololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
EsmololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
Etacrynic acidRacepinephrine may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtafedrineRacepinephrine may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Ethosuximide.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Racepinephrine.Withdrawn
EtomidateRacepinephrine may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Fendiline.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Racepinephrine.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Fenozolone.Experimental
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Racepinephrine.Approved, Illicit, Investigational, Vet Approved
Fish oilThe risk or severity of hypotension can be increased when Racepinephrine is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Flunarizine.Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Racepinephrine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Racepinephrine is combined with Fluspirilene.Approved, Investigational
FormoterolRacepinephrine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Racepinephrine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved
FurosemideRacepinephrine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Racepinephrine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Racepinephrine is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Ganciclovir.Approved, Investigational
GuanabenzRacepinephrine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineRacepinephrine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HarmalineHarmaline may increase the hypertensive activities of Racepinephrine.Experimental
HexoprenalineRacepinephrine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineRacepinephrine may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Racepinephrine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Racepinephrine.Experimental
HydrochlorothiazideRacepinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Racepinephrine.Approved, Vet Approved
HydroflumethiazideRacepinephrine may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Racepinephrine.Approved
IloperidoneIloperidone may increase the antihypertensive activities of Racepinephrine.Approved
ImipramineImipramine may increase the antihypertensive activities of Racepinephrine.Approved
IndacaterolRacepinephrine may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideRacepinephrine may increase the hypokalemic activities of Indapamide.Approved
IndenololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Racepinephrine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Racepinephrine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Racepinephrine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Racepinephrine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Racepinephrine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Racepinephrine.Approved
IsoetarineRacepinephrine may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneRacepinephrine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Racepinephrine.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Racepinephrine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Isradipine.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Racepinephrine.Approved
LacidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Lamotrigine.Approved, Investigational
LandiololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Racepinephrine is combined with Levetiracetam.Approved, Investigational
LevobetaxololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Racepinephrine.Approved, Investigational
LevosalbutamolRacepinephrine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Lidoflazine.Experimental
LinezolidLinezolid may increase the hypertensive activities of Racepinephrine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
LisurideLisuride may increase the hypertensive activities of Racepinephrine.Approved, Investigational
LofepramineLofepramine may decrease the antihypertensive activities of Racepinephrine.Experimental
LofexidineRacepinephrine may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Loperamide.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive activities of Racepinephrine.Illicit, Investigational, Withdrawn
Magnesium sulfateThe risk or severity of hypotension can be increased when Racepinephrine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Racepinephrine.Withdrawn
MedetomidineRacepinephrine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefenorexThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Mefenorex.Experimental
MelitracenMelitracen may decrease the antihypertensive activities of Racepinephrine.Experimental, Investigational
MentholThe risk or severity of hypotension can be increased when Racepinephrine is combined with Menthol.Approved
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Racepinephrine.Approved
MepindololMepindolol may decrease the bronchodilatory activities of Racepinephrine.Experimental
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Racepinephrine.Approved, Investigational
MetergolineMetergoline may increase the hypertensive activities of Racepinephrine.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Racepinephrine.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Racepinephrine.Approved, Investigational
MethoxyphenamineRacepinephrine may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Methsuximide.Approved
MethyclothiazideRacepinephrine may increase the hypokalemic activities of Methyclothiazide.Approved
MethyldopaRacepinephrine may decrease the vasoconstricting activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Racepinephrine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
MethysergideMethysergide may increase the hypertensive activities of Racepinephrine.Approved
MetolazoneRacepinephrine may increase the hypokalemic activities of Metolazone.Approved
MetoprololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Racepinephrine is combined with Mibefradil.Investigational, Withdrawn
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Racepinephrine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Racepinephrine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Racepinephrine.Approved
MirabegronRacepinephrine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Racepinephrine.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Racepinephrine.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Racepinephrine.Approved, Investigational
MoxonidineRacepinephrine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Racepinephrine.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Racepinephrine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Racepinephrine is combined with Naftopidil.Investigational
NaphazolineRacepinephrine may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Racepinephrine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Racepinephrine.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive activities of Racepinephrine.Approved, Investigational
NiguldipineNiguldipine may increase the antihypertensive activities of Racepinephrine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Nitrendipine.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Racepinephrine.Approved
NorfenefrineRacepinephrine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineNortriptyline may increase the antihypertensive activities of Racepinephrine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Racepinephrine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Racepinephrine.Withdrawn
OctopamineRacepinephrine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
OlodaterolRacepinephrine may decrease the vasoconstricting activities of Olodaterol.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Racepinephrine.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Racepinephrine.Approved
OtiloniumThe risk or severity of hypotension can be increased when Racepinephrine is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may decrease the bronchodilatory activities of Racepinephrine.Approved
OxyfedrineRacepinephrine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Racepinephrine.Approved, Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Racepinephrine.Approved
PargylinePargyline may increase the hypertensive activities of Racepinephrine.Approved
Patent BlueThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Racepinephrine.Approved, Investigational
PentoxifyllinePentoxifylline may increase the hypotensive activities of Racepinephrine.Approved, Investigational
PergolidePergolide may increase the hypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved, Withdrawn
PhendimetrazineRacepinephrine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Racepinephrine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Racepinephrine.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Racepinephrine.Approved, Illicit
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Racepinephrine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Racepinephrine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Racepinephrine.Approved, Illicit
PhentolaminePhentolamine may increase the antihypertensive activities of Racepinephrine.Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Racepinephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Racepinephrine.Approved, Vet Approved, Withdrawn
PinaveriumThe risk or severity of hypotension can be increased when Racepinephrine is combined with Pinaverium.Approved
PindololPindolol may decrease the bronchodilatory activities of Racepinephrine.Approved, Investigational
PirbuterolRacepinephrine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiretanideRacepinephrine may increase the hypokalemic activities of Piretanide.Approved
PirlindolePirlindole may increase the hypertensive activities of Racepinephrine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Racepinephrine.Withdrawn
PizotifenPizotifen may increase the antihypertensive activities of Racepinephrine.Approved
Platelet Activating FactorRacepinephrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazideRacepinephrine may increase the hypokalemic activities of Polythiazide.Approved
PractololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may increase the antihypertensive activities of Racepinephrine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Prenylamine.Withdrawn
ProcaineProcaine may increase the hypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypertensive activities of Racepinephrine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Racepinephrine.Approved, Investigational
PromazinePromazine may increase the antihypertensive activities of Racepinephrine.Approved, Vet Approved
PropafenoneRacepinephrine may increase the atrioventricular blocking (AV block) activities of Propafenone.Approved
PropericiazinePropericiazine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Racepinephrine.Approved
PropiverinePropiverine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
PropranololPropranolol may decrease the bronchodilatory activities of Racepinephrine.Approved, Investigational
ProtokylolRacepinephrine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may decrease the antihypertensive activities of Racepinephrine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may increase the antihypertensive activities of Racepinephrine.Approved
QuinethazoneRacepinephrine may increase the hypokalemic activities of Quinethazone.Approved
QuinidineQuinidine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
RactopamineRacepinephrine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RasagilineRasagiline may increase the hypertensive activities of Racepinephrine.Approved
ReproterolRacepinephrine may decrease the vasoconstricting activities of Reproterol.Investigational
RilmenidineRacepinephrine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolRacepinephrine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
RitobegronRacepinephrine may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Racepinephrine.Approved, Investigational
RomifidineRacepinephrine may decrease the vasoconstricting activities of Romifidine.Vet Approved
SafrazineSafrazine may increase the hypertensive activities of Racepinephrine.Withdrawn
SalbutamolRacepinephrine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolRacepinephrine may decrease the vasoconstricting activities of Salmeterol.Approved
SelegilineSelegiline may increase the hypertensive activities of Racepinephrine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Racepinephrine is combined with Seletracetam.Investigational
SildenafilSildenafil may increase the hypotensive activities of Racepinephrine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Racepinephrine.Approved
SolabegronRacepinephrine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may decrease the bronchodilatory activities of Racepinephrine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Racepinephrine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Racepinephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Racepinephrine.Approved, Investigational
TalinololRacepinephrine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
Tedizolid phosphateTedizolid Phosphate may increase the hypertensive activities of Racepinephrine.Approved
TerazosinTerazosin may increase the antihypertensive activities of Racepinephrine.Approved
TerbutalineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
TergurideTerguride may increase the hypertensive activities of Racepinephrine.Experimental
TerodilineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Terodiline.Experimental
TertatololTertatolol may decrease the bronchodilatory activities of Racepinephrine.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Tetrahydropalmatine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Racepinephrine.Approved
TheophyllineTheophylline may increase the hypotensive activities of Racepinephrine.Approved
ThioproperazineThioproperazine may increase the antihypertensive activities of Racepinephrine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Racepinephrine.Approved, Withdrawn
TianeptineTianeptine may decrease the antihypertensive activities of Racepinephrine.Approved, Investigational
TimololTimolol may decrease the bronchodilatory activities of Racepinephrine.Approved
TizanidineRacepinephrine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Racepinephrine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Racepinephrine is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Racepinephrine.Approved
TorasemideRacepinephrine may increase the hypokalemic activities of Torasemide.Approved
TramazolineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Tramazoline.Investigational
TranilastThe risk or severity of hypotension can be increased when Racepinephrine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Racepinephrine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Tretoquinol.Experimental
TrichlormethiazideRacepinephrine may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Racepinephrine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Racepinephrine is combined with Trimethadione.Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Racepinephrine.Approved
TulobuterolRacepinephrine may decrease the vasoconstricting activities of Tulobuterol.Investigational
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Racepinephrine.Investigational, Nutraceutical
UdenafilUdenafil may increase the hypotensive activities of Racepinephrine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Racepinephrine.Investigational
VardenafilVardenafil may increase the hypotensive activities of Racepinephrine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Racepinephrine.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Racepinephrine.Approved
VerapamilVerapamil may increase the antihypertensive activities of Racepinephrine.Approved
VilanterolRacepinephrine may decrease the vasoconstricting activities of Vilanterol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Racepinephrine is combined with WIN 55212-2.Experimental
XamoterolRacepinephrine may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineRacepinephrine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineRacepinephrine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Racepinephrine.Approved
ZonisamideThe risk or severity of hypotension can be increased when Racepinephrine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Racepinephrine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Langley JM, Smith MB, LeBlanc JC, Joudrey H, Ojah CR, Pianosi P: Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]. BMC Pediatr. 2005 May 5;5(1):7. doi: 10.1186/1471-2431-5-7. [PubMed:15876347]
  2. Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K: The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. Arch Pediatr Adolesc Med. 1995 Jun;149(6):686-92. [PubMed:7767427]
  3. 14. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 174-175, 181-182). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
PubChem Substance
347911128
Wikipedia
Racepinephrine
FDA label
Download (625 KB)
MSDS
Download (59.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableNot Yet RecruitingPreventionDysphonia / Postoperative pain / Swallowing Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Aerosol, sprayRespiratory (inhalation).594 mg/.12mL
SolutionRespiratory (inhalation)11.25 mg/.5mL
SolutionRespiratory (inhalation)2.25 %
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
PropertyValueSource
melting point (°C)157MSDS
water solubilitySolubleMSDS
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da

Drug created on December 03, 2015 09:51 / Updated on August 02, 2018 07:55